Immunohematology Market Report 2025

The immunohematology market size has grown steadily in recent years. It will grow from $2.46 billion in 2024 to $2.57 billion in 2025 at a compound annual growth rate (CAGR) of 4.6%. The growth in the historic period can be attributed to advancements in blood transfusion science, the prevalence of blood disorders, the expansion of blood banks, government initiatives for blood safety, increased surgical procedures, and awareness of transfusion-related risks.

The immunohematology market size is expected to see strong growth in the next few years. It will grow to $3.24 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to increasing demand for point-of-care testing, emergence of novel blood products, expansion of healthcare infrastructure, genetic testing for blood compatibility, and regulatory support for blood safety. Major trends in the forecast period include automation and high-throughput systems, molecular blood typing methods, antibody detection techniques, patient blood management programs, integration of ai in analysis, telemedicine integration.

The anticipated rise in the prevalence of hematological disorders is set to drive the growth of the immunohematology market in the foreseeable future. Hematological disorders, affecting blood components such as red blood cells, white blood cells, platelets, and plasma, necessitate the use of immunohematology for safe and effective blood transfusions. This helps prevent transfusion reactions arising from incompatible blood types or the presence of antibodies in the recipient's blood. Immunohematology techniques also play a crucial role in diagnosing and treating diseases impacting the immune system, with potential implications for the hematological system. For instance, Cancer Research UK reported an expected increase in new leukemia cases due to hematological disorders in the UK, rising from approximately 12,400 cases in 2023-2025 to around 14,500 cases in 2038-2040. Thus, the escalating prevalence of hematological disorders is a key driver behind the growth of the immunohematology market.

The growth of the immunohematology market is anticipated to be driven by the increasing aging population. An aging population refers to a demographic trend marked by a higher proportion of elderly individuals within a society. Immunohematology plays a crucial role in meeting the transfusion needs of this demographic, ensuring the safe use of blood products, and facilitating medical interventions for older adults. For instance, in January 2024, the Population Reference Bureau, a U.S.-based nonprofit organization, projected that the number of Americans aged 65 and older will rise from 58 million in 2022 to 82 million by 2050, representing a 47% increase. Additionally, this age group's share of the total population is expected to grow from 17% to 23% during the same period. Therefore, the aging population is a significant factor driving the expansion of the immunohematology market.

Leading companies in the immunohematology market are focused on creating innovative diagnostic solutions, such as soluble recombinant proteins that can mitigate the interference caused by the cancer therapy daratumumab. Soluble recombinant proteins are produced using recombinant DNA technology, maintaining their proper structure and functionality in a soluble form within a host cell or solution, making them suitable for research and therapeutic applications. For example, in November 2023, Grifols, S.A., a pharmaceutical company based in Spain, introduced the Grifols sCD38 solution. This product is the first-ever soluble recombinant protein developed specifically to address the interference that daratumumab causes in essential blood transfusion compatibility testing. Targeted at patients with multiple myeloma, this groundbreaking solution prevents daratumumab from binding to CD38 proteins on red blood cells, ensuring accurate pre-transfusion test results. By streamlining the processes of screening, identification, and crossmatching, Grifols sCD38 improves blood transfusion protocols and reduces delays in administering lifesaving transfusions.

Major companies operating in the immunohematology market are innovating by introducing new products such as self-sampling blood collection products to enhance their market profitability. Self-sampling blood collection involves individuals collecting their own blood samples for diagnostic purposes without the need for healthcare professionals. For example, in February 2023, Capitainer launched CapitainerB 50, a self-sampling blood collection device that protects samples from contamination. The microsampling technology employed ensures precise quantitative sampling comparable to conventional pipetting.

In March 2023, Werfen, S.A., a diagnostic care company based in Spain, completed the acquisition of Immucor Inc. for approximately $2 billion. This strategic move aimed to expand Werfen's capabilities in specialized diagnostic testing, particularly within diagnostic solutions. Immucor Inc., a transfusion diagnostics company based in Spain, focuses on providing safe, accessible, and affordable blood tests.

Major companies operating in the immunohematology market include Ortho Clinical Diagnostics Inc., Immunocor Inc., Abbott Laboratories, Siemens Healthineers AG, Grifols S.A., Beckman Coulter Inc., Thermo Fisher Scientific Inc., Becton Dickinson and Company, Merck Co. & KGaA, Bio-Rad Laboratories, Sysmex Corporation, Danaher Corporation, Biosystems S.A., Roche Holdings AG, Mindray Medical International Limited, F.Hoffmann La-Roche Ltd., Biotest AG, Cardinal Health Inc., Quotient Limited, DiaSorin S.p.A., Lorne Laboratories Ltd., Biokit S.A., Avox Technologies, Diagnostic Automation/Cortez Diagnostics Inc., Inno-train Diagnostik GmbH, Drucker Diagnostics Inc., Immundia Diagnostics Pvt. Ltd.

North America was the largest region in the immunohematology market in 2024. Asia-Pacific is expected to be the fastest growing region in the global immunohematology market during the forecast period. The regions covered in the immunohematology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the immunohematology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Immunohematology is a subfield of laboratory medicine that focuses on the study of blood groups and the immune response of the body to foreign substances, particularly in the context of blood transfusions. Immunohematological techniques are employed to identify and address diagnostic issues in patients with hematological conditions, including auto-immune hemolytic anemia.

The main components of immunohematology include analyzers and systems, along with reagents. Analyzers and systems are automated instruments designed for blood typing and antibody screening. Various technologies are utilized in this field, such as biochips, erythrocyte-magnetized technology (EMT), gel cards, microplates, and polymerase chain reaction (PCR). These technologies are applied in the treatment of various diseases such as HIV and hepatitis. The diverse applications encompass pretransfusion testing, investigation of immune hemolysis, perinatal testing, blood group phenotyping, leucocyte and platelet serology. The end-users of immunohematology products include blood banks, diagnostic and reference laboratories, hospitals, as well as academic and research institutes.

The immunohematology market research report is one of a series of new reports that provides immunohematology optical components market statistics, including immunohematology optical components industry global market size, regional shares, competitors with a immunohematology optical components market share, detailed immunohematology optical components market segments, market trends and opportunities, and any further data you may need to thrive in the immunohematology optical components industry. This immunohematology optical components market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The immunohematology market includes revenues earned by entities by providing blood banking and transfusion medicine services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.